Reprint: Good laboratory practice: preventing introduction of bias at the bench

Area of Science:

• Neuroscience
• Translational Medicine
• Biomedical Research

Background:

• Drugs effective in animal models of cerebral ischemia often fail in human stroke trials.
• Systematic bias in animal study design, conduct, and reporting may overstate neuroprotective efficacy.
• This discrepancy hinders the development of effective treatments for human stroke.

Purpose of the Study:

• To identify and address systematic biases in preclinical animal research for stroke.
• To propose a series of measures to improve the reliability of animal models of cerebral ischemia.
• To enhance the translational validity of neuroprotection research for human stroke.

Main Methods:

• Review of existing literature on bias in animal stroke models.
• Development of a framework for reducing bias in experimental design.
• Recommendations for standardized conduct and reporting of animal experiments.
• Focus on measures to mitigate overstatement of neuroprotective effects.

Main Results:

• Identified key sources of systematic bias in animal stroke research.
• Outlined specific methodological improvements for study design (e.g., randomization, blinding).
• Proposed guidelines for transparent reporting to ensure reproducibility.
• Highlighted the impact of bias on the failure of neuroprotective drugs in clinical trials.

Conclusions:

• Improving the quality and reducing bias in animal stroke models is crucial for successful translation to human patients.
• Implementing proposed measures can enhance the predictive value of preclinical research.
• This approach aims to increase the likelihood of developing effective neuroprotective therapies for stroke.
• Addressing bias is essential for the research community to overcome the translational gap in stroke treatment development.